Comparing survival, fat loss and recovery
The measurements differ because the treatment questions differ. A fair comparison preserves those differences.
What actually changed?
Comparing the sepsis and recovery records exposes the weakness of a single score for “peptide evidence”. The sepsis trial measured deaths. The tesamorelin trials measured abdominal fat in a particular clinical setting. A small BPC-157 safety pilot looked for immediate problems in healthy adults. Those studies differ in both ambition and what they can answer.
The table below starts with the outcome, then attaches the population and comparison. Its rows are separate clinical records. It would be misleading to rank the compounds by the largest percentage: each percentage has a different denominator and meaning.
| Clinical question | Result in this record | Scope |
|---|---|---|
| Thymosin alpha-1 and sepsis survival | TESTS found no statistically significant 28-day mortality benefit | Adults with sepsis in a phase 3 placebo-controlled trial |
| Tesamorelin and abdominal fat | Visceral fat fell during treatment | Adults with HIV and abdominal fat accumulation |
| Retatrutide and weight | Substantial average weight loss at 48 weeks | Adults in a phase 2 obesity trial |
| BPC-157 and injury recovery | Rigorous large-scale human efficacy trials remain lacking | Animal repair studies and very limited human pilots |
The disappointment in the first row leaves a stronger answer about that survival claim than the sparse record in the last row supplies about recovery. Both limit enthusiasm, for quite different reasons.
A measured change and a broader benefit
The tesamorelin fat finding and retatrutide weight finding deserve recognition. In obesity or abnormal fat distribution, a change in body composition can itself be a meaningful treatment result.
Attaching extra benefits to those measurements feels unjustified to me. Less liver fat does not by itself establish lasting protection from liver disease. A higher hormone concentration does not by itself establish longer life. Those are additional hypotheses, with additional outcomes to test.
The retrospective thymosin alpha-1 COVID-19 study illustrates another distinction. It recorded a survival association, a highly relevant outcome, while its non-randomised design left causal uncertainty. Both the outcome and the way treatment was assigned shape the conclusion.
Approval and the cost of uncertainty
Tesamorelin has US approval for a defined HIV-related fat indication. Retatrutide remains investigational; BPC-157 remains an unapproved research compound; thymosin alpha-1 has international approvals without US medicine approval. Calling them all peptides changes none of those boundaries.
The uncertainties also differ. Tesamorelin raises questions about growth factors, glucose and fat returning after treatment ends. Retatrutide brings gastrointestinal adverse effects and pulse changes alongside unanswered longer-term questions. BPC-157 leaves basic human efficacy and safety poorly characterised. Thymosin alpha-1 requires attention to the immune setting and to the failed larger sepsis test.
I grant each record the conclusion it can support, with the inconvenient findings included. Clinical assessment still has to account for the individual person's illness, medicines and reasons a treatment may be unsuitable. These essays cannot supply that assessment.